Home The Word Brain My Amedeo FAQ Privacy About   

2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Free Subscription

Articles published in Am J Hematol

Retrieve available abstracts of 262 articles:
HTML format

Single Articles

    May 2024
  1. NJOKU F, Pugh N, Brambilla D, Kroner B, et al
    Mortality in adults with sickle cell disease: Results from the sickle cell disease implementation consortium (SCDIC) registry.
    Am J Hematol. 2024;99:900-909.
    PubMed     Abstract available

  2. GRIFFIN M, Kelly R, Brindel I, Maafa L, et al
    Real-world experience of pegcetacoplan in paroxysmal nocturnal hemoglobinuria.
    Am J Hematol. 2024;99:816-823.
    PubMed     Abstract available

    April 2024
  3. YOSHIMI A, Noellke P, Stary J, Kallay K, et al
    Comparison of outcomes of immunosuppressive therapy with rabbit versus horse antithymocyte globulin and cyclosporine a in children with acquired severe aplastic anemia.
    Am J Hematol. 2024 Apr 15. doi: 10.1002/ajh.27334.

  4. JACKSON TA, Buscetta AJ, Ramirez HC, Bonham VL Jr, et al
    Leg ulcers are indicators of systemic dysfunction in individuals with sickle cell disease.
    Am J Hematol. 2024;99:767-769.
    PubMed     Abstract available

  5. FATTIZZO B, Roth A, Broome CM, Khan U, et al
    COVID-19 vaccine safety and immunogenicity in patients with cold agglutinin disease receiving concomitant sutimlimab.
    Am J Hematol. 2024;99:789-791.
    PubMed     Abstract available

  6. EAPEN M, Kou J, Andreansky M, Bhatia M, et al
    Long-term outcomes after unrelated donor transplantation for severe sickle cell disease on the BMT CTN 0601 trial.
    Am J Hematol. 2024;99:785-788.

  7. ITO S, Pandya A, Hauser RG, Krishnamurti L, et al
    Decreasing alloimmunization-specific mortality in sickle cell disease in the United States: Cost-effectiveness of a shared transfusion resource.
    Am J Hematol. 2024;99:570-576.
    PubMed     Abstract available

  8. ALLALI S, Galacteros F, Oevermann L, Cannas G, et al
    Hydroxyurea is associated with later onset of acute splenic sequestration crisis in sickle cell disease: Lessons from the European Sickle Cell Disease Cohort-Hydroxyurea (ESCORT-HU) study.
    Am J Hematol. 2024;99:555-561.
    PubMed     Abstract available

    March 2024
  9. GIARDINO S, Eikema DJ, Piepenbroek B, Algeri M, et al
    HLA-haploidentical stem cell transplantation in children with inherited bone marrow failure syndromes: A retrospective analysis on behalf of EBMT severe aplastic Anemia and pediatric diseases working parties.
    Am J Hematol. 2024 Mar 18. doi: 10.1002/ajh.27293.
    PubMed     Abstract available

  10. SHORT V, Allen R, Earley CJ, Bahrain H, et al
    A randomized double-blind pilot study to evaluate the efficacy, safety, and tolerability of intravenous iron versus oral iron for the treatment of restless legs syndrome in patients with iron deficiency anemia.
    Am J Hematol. 2024 Mar 13. doi: 10.1002/ajh.27290.
    PubMed     Abstract available

  11. SICA M, Notaro R
    The inhibition of several components of terminal complement pathway results in C3 binding to PNH red blood cells.
    Am J Hematol. 2024;99:505-507.
    PubMed     Abstract available

  12. MUSALLAM KM, Barella S, Origa R, Ferrero GB, et al
    'Phenoconversion' in adult patients with beta-thalassemia.
    Am J Hematol. 2024;99:490-493.
    PubMed     Abstract available

  13. JACOBS JW, Booth GS, Woo JS, Adkins BD, et al
    How the United States syphilis epidemic may portend a resurgence of an unusual hematologic condition: The connection between syphilis and paroxysmal cold hemoglobinuria.
    Am J Hematol. 2024;99:484-485.
    PubMed     Abstract available

  14. CORBACIOGLU S, Frangoul H, Locatelli F, Hobbs W, et al
    Defining curative endpoints for transfusion-dependent beta-thalassemia in the era of gene therapy and gene editing.
    Am J Hematol. 2024;99:422-429.
    PubMed     Abstract available

  15. LOCATELLI F, Corbacioglu S, Hobbs W, Frangoul H, et al
    Defining curative endpoints for sickle cell disease in the era of gene therapy and gene editing.
    Am J Hematol. 2024;99:430-438.
    PubMed     Abstract available

    February 2024
  16. POWER-HAYS A, Tomlinson GA, Tshilolo L, Santos B, et al
    Reducing transfusion utilization for children with sickle cell anemia in sub-Saharan Africa with hydroxyurea: Analysis from the phase I/II REACH trial.
    Am J Hematol. 2024 Feb 8. doi: 10.1002/ajh.27244.
    PubMed     Abstract available

  17. ABDULLAHI SU, Sunusi S, Aminu H, Umar R, et al
    Transcranial doppler velocity in iron-deficient Nigerian children with sickle cell anemia.
    Am J Hematol. 2024 Feb 7. doi: 10.1002/ajh.27230.
    PubMed     Abstract available

  18. TEFFERI A, Pardanani A, Gangat N
    Momelotinib expands the therapeutic armamentarium for myelofibrosis: Impact on hierarchy of treatment choices.
    Am J Hematol. 2024;99:300-308.
    PubMed     Abstract available

  19. SOUISSI M, Daliphard S, Picard V, Lebigot E, et al
    Elevated MCHC reveals a Southeast Asian Ovalocytosis.
    Am J Hematol. 2024;99:331-332.

  20. CHEN M, Hankins JS, Zhang M, Ataga KI, et al
    Comparative pharmacovigilance assessment of adverse events associated with the use of hydroxyurea, L-glutamine, voxelotor, and crizanlizumab in sickle cell disease.
    Am J Hematol. 2024;99:E37-E41.
    PubMed     Abstract available

  21. AFZALI-HASHEMI L, Dovern E, Baas KPA, Schrantee A, et al
    Cerebral hemodynamics and oxygenation in adult patients with sickle cell disease after stem cell transplantation.
    Am J Hematol. 2024;99:163-171.
    PubMed     Abstract available

  22. GARBOWSKI MW, Ugidos M, Risueno A, Shetty JK, et al
    Luspatercept stimulates erythropoiesis, increases iron utilization, and redistributes body iron in transfusion-dependent thalassemia.
    Am J Hematol. 2024;99:182-192.
    PubMed     Abstract available

    January 2024
  23. SHAGIDOV D, Guttmann-Raviv N, Cunat S, Frech L, et al
    A newly identified ferritin L-subunit variant results in increased proteasomal subunit degradation, impaired complex assembly, and severe hypoferritinemia.
    Am J Hematol. 2024;99:12-20.
    PubMed     Abstract available

  24. SEIDL E, Wilson D, Odame I, Kirby-Allen M, et al
    Lung function decline in children with sickle cell disease treated with hydroxyurea.
    Am J Hematol. 2024;99:E19-E21.

    December 2023
  25. PINTO VM, Romano N, Balocco M, Carrara P, et al
    Reduction of extramedullary erythropoiesis and amelioration of anemia in a beta-thalassemia patient treated with thalidomide.
    Am J Hematol. 2023 Dec 26. doi: 10.1002/ajh.27189.
    PubMed     Abstract available

  26. SOULIE A, Kamdem A, Neumann F, Hau I, et al
    Clinical events in a long-term prospective neonatal cohort of children with sickle cell disease: Evidence for a high disease burden without systematic preventive intensification with hydroxyurea.
    Am J Hematol. 2023;98:E395-E398.

  27. HATEM A, Esperti S, Murciano N, Qiao M, et al
    Adverse effects of delta-9-tetrahydrocannabinol on sickle red blood cells.
    Am J Hematol. 2023;98:E383-E386.
    PubMed     Abstract available

  28. BARAKAT A, Jasuja R, Tomlinson L, Wenzel Z, et al
    Effects of 2,3-DPG knockout on SCD phenotype in Townes SCD model mice.
    Am J Hematol. 2023;98:1838-1846.
    PubMed     Abstract available

    November 2023
  29. KHO S, Siregar NC, Qotrunnada L, Fricot A, et al
    Retention of uninfected red blood cells causing congestive splenomegaly is the major mechanism of anemia in malaria.
    Am J Hematol. 2023 Nov 27. doi: 10.1002/ajh.27152.
    PubMed     Abstract available

  30. HONG HG, Gouveia MH, Ogwang MD, Kerchan P, et al
    Sickle cell allele HBB-rs334(T) is associated with decreased risk of childhood Burkitt lymphoma in East Africa.
    Am J Hematol. 2023 Nov 27. doi: 10.1002/ajh.27149.
    PubMed     Abstract available

  31. KUTER DJ, Piatek C, Roth A, Siddiqui A, et al
    Fostamatinib for warm antibody autoimmune hemolytic anemia: Phase 3, randomized, double-blind, placebo-controlled, global study (FORWARD).
    Am J Hematol. 2023 Nov 6. doi: 10.1002/ajh.27144.
    PubMed     Abstract available

  32. PINCEZ T, Lettre G
    Re-assessing the effect of fetal hemoglobin on stroke in the Cooperative Study of Sickle Cell Disease.
    Am J Hematol. 2023;98:E309-E311.

  33. THOMAS B, Visanica S, Poussing S, Gerard D, et al
    Is this really thalassemia?
    Am J Hematol. 2023;98:1814-1815.

  34. Withdrawal: "Primary prevention of sickle cell disease using preimplantation genetic testing and in vitro fertilization is cost-effective." Christina N. Cordeiro Mitchell, Apoorva Pradhan, Bhuchitra Singh, Rakhi P. Naik, Valerie L. Baker, Sophie M. La
    Am J Hematol. 2023;98:1819.
    PubMed     Abstract available

  35. DI MAURO M, El Hoss S, Nardo-Marino A, Stuart-Smith S, et al
    Males with sickle cell disease have higher risks of cerebrovascular disease, increased inflammation, and a reduced response to hydroxyurea.
    Am J Hematol. 2023;98:E341-E344.
    PubMed     Abstract available

    October 2023
  36. CASIMIR M, Colard M, Dussiot M, Roussel C, et al
    Erythropoietin downregulates red blood cell clearance, increasing transfusion efficacy in severely anemic recipients.
    Am J Hematol. 2023 Oct 4. doi: 10.1002/ajh.27117.
    PubMed     Abstract available

  37. ARCHER NM, Gnangnon B, Mikdar M, Ciuculescu MF, et al
    F-erythrocytes promote Plasmodium falciparum proliferation in sickle cell disease.
    Am J Hematol. 2023;98:1598-1605.
    PubMed     Abstract available

  38. STEINBERG MH, Gladwin MT
    "Severity" in adult sickle cell disease.
    Am J Hematol. 2023;98:1508-1511.

  39. WALSH PS, Brousseau DC, Coleman KD
    Return visits after emergency department treatment for sickle cell pain crises.
    Am J Hematol. 2023;98:E266-E268.

    September 2023
  40. VAN DIJK MJ, van Oirschot BA, Harrison AN, Recktenwald SM, et al
    A novel missense variant in ATP11C is associated with reduced red blood cell phosphatidylserine flippase activity and mild hereditary hemolytic anemia.
    Am J Hematol. 2023 Sep 6. doi: 10.1002/ajh.27088.
    PubMed     Abstract available

  41. PORTER JB, Scrimgeour A, Martinez A, James L, et al
    SLN124, a GalNAc conjugated 19-mer siRNA targeting tmprss6, reduces plasma iron and increases hepcidin levels of healthy volunteers.
    Am J Hematol. 2023;98:1425-1435.
    PubMed     Abstract available

  42. LIU H, Xia L, Weng J, Zhang F, et al
    Efficacy and safety of the C5 inhibitor crovalimab in complement inhibitor-naive patients with PNH (COMMODORE 3): A multicenter, Phase 3, single-arm study.
    Am J Hematol. 2023;98:1407-1414.
    PubMed     Abstract available

  43. ELALFY MS, Hamdy M, Adly A, Ebeid FSE, et al
    Efficacy and safety of early-start deferiprone in infants and young children with transfusion-dependent beta thalassemia: Evidence for iron shuttling to transferrin in a randomized, double-blind, placebo-controlled, clinical trial (START).
    Am J Hematol. 2023;98:1415-1424.
    PubMed     Abstract available

  44. MUSALLAM KM, Lombard L, Kistler KD, Arregui M, et al
    Epidemiology of clinically significant forms of alpha- and beta-thalassemia: A global map of evidence and gaps.
    Am J Hematol. 2023;98:1436-1451.
    PubMed     Abstract available

  45. VON SIEBENTHAL HK, Moretti D, Zimmermann MB, Stoffel NU, et al
    Effect of dietary factors and time of day on iron absorption from oral iron supplements in iron deficient women.
    Am J Hematol. 2023;98:1356-1363.
    PubMed     Abstract available

  46. NYANGASA S, Solomon D, Njiro B, Faisal A, et al
    The rate and pattern of fetal hemoglobin decline adjusted to sickle cell status of newborns in Dar es Salaam, Tanzania: A prospective cohort study.
    Am J Hematol. 2023;98:E241-E243.
    PubMed     Abstract available

  47. PIRAN S, Alhomsi N, Warkentin TE
    Recurrent severe thrombocytopenia in critical illness complicated by hemolysis.
    Am J Hematol. 2023;98:1490-1496.

    August 2023
  48. NAIR M, Choudhury SS, Rani A, Solomi C 5th, et al
    The complex relationship between iron status and anemia in pregnant and postpartum women in India: Analysis of two Indian study cohorts of uncomplicated pregnancies.
    Am J Hematol. 2023 Aug 31. doi: 10.1002/ajh.27059.
    PubMed     Abstract available

  49. AGARWAL S, Stanek JR, Vesely SK, Creary SE, et al
    Pregnancy-related thromboembolism in women with sickle cell disease: An analysis of National Medicaid Data.
    Am J Hematol. 2023 Aug 8. doi: 10.1002/ajh.27045.
    PubMed     Abstract available

  50. PATNAIK MM, Tefferi A
    Luspatercept use for lower risk myelodysplastic syndromes: Active but not enough.
    Am J Hematol. 2023;98:1171-1175.

  51. SACHDEV V, Limerick E, Nguyen ML, Li W, et al
    Cardiac effects 2 years after successful non-myeloablative human leukocyte antigen-matched related donor hematopoietic cell transplants in sickle cell disease.
    Am J Hematol. 2023;98:E219-E221.

  52. ROTH A, Barcellini W, D'Sa S, Miyakawa Y, et al
    Sustained inhibition of complement C1s with sutimlimab over 2 years in patients with cold agglutinin disease.
    Am J Hematol. 2023;98:1246-1253.
    PubMed     Abstract available

  53. LANINO L, Restuccia F, Perego A, Ubezio M, et al
    Real-world efficacy and safety of luspatercept and predictive factors of response in patients with lower risk myelodysplastic syndromes with ring sideroblasts.
    Am J Hematol. 2023;98:E204-E208.

  54. GROS M, Pondarre C, Arnaud C, Kamdem A, et al
    Lung function after matched-related donor allogeneic hematopoietic stem cell transplantation in children with sickle cell disease.
    Am J Hematol. 2023;98:E212-E215.

  55. LIU A, Kremyanskaya M, Mehrazin R, Si Q, et al
    Erythropoietin-secreting metanephric adenoma presenting as erythrocytosis.
    Am J Hematol. 2023 Aug 1. doi: 10.1002/ajh.27047.

    July 2023
  56. ZHANG L, Zhao J, Li R, Pan H, et al
    Low risk of relapse in aplastic anemia patients after SARS-CoV-2 omicron infection: A prospective NICHE cohort.
    Am J Hematol. 2023 Jul 14. doi: 10.1002/ajh.27028.

  57. MCGLOTHLIN J, Abeykoon J, Al-Hattab E, Ashrani AA, et al
    Bortezomib and daratumumab in refractory autoimmune hemolytic anemia.
    Am J Hematol. 2023 Jul 7. doi: 10.1002/ajh.27025.

  58. POWERS JM, Auerbach M
    When taking iron, a glass of orange juice a day keeps anemia away.
    Am J Hematol. 2023 Jul 4. doi: 10.1002/ajh.27017.

  59. RIBEIL JA, Pollock G, Frangoul H, Steinberg MH, et al
    An integrated therapeutic approach to sickle cell disease management beyond infancy.
    Am J Hematol. 2023;98:1087-1096.
    PubMed     Abstract available

  60. ALLALI S, Elie J, Mayrand L, de Montalembert M, et al
    Sputum IL-6 level as a potential predictor of acute chest syndrome during vaso-occlusive crisis in children with sickle cell disease: Exploratory prospective prognostic accuracy study.
    Am J Hematol. 2023;98:E175-E178.

  61. D'ALESSANDRO A, Nouraie SM, Zhang Y, Cendali F, et al
    In vivo evaluation of the effect of sickle cell hemoglobin S, C and therapeutic transfusion on erythrocyte metabolism and cardiorenal dysfunction.
    Am J Hematol. 2023;98:1017-1028.
    PubMed     Abstract available

    June 2023
  62. URIO F, Nkya S, Mgaya J, Rooks H, et al
    Gender effect on production and enrichment of F cell numbers in sickle cell disease patients in Tanzania.
    Am J Hematol. 2023;98:E139-E141.

  63. PINTO VM, Russo R, Quintino S, Rosato BE, et al
    Coinheritance of PIEZO1 variants and multi-locus red blood cell defects account for the symptomatic phenotype in beta-thalassemia carriers.
    Am J Hematol. 2023;98:E130-E133.
    PubMed     Abstract available

  64. BORDONI V, Casale M, Pinto VM, Carsetti R, et al
    Inflammatory and senescence-associated mediators affect the persistence of humoral response to COVID-19 mRNA vaccination in transfusion-dependent beta-thalassemic patients.
    Am J Hematol. 2023;98:E145-E147.

  65. CHEN PH, Gorshein E, Tormey C, Siddon AJ, et al
    "Double-hit" ineffective erythropoiesis-concurrent beta-thalassemia with alpha-gene triplication and myelodysplastic syndrome with SF3B1 mutation.
    Am J Hematol. 2023;98:984-988.

    May 2023
    Complement inhibition in medicine: Hematology and beyond; complement inhibition in hematology: PNH and beyond.
    Am J Hematol. 2023;98 Suppl 4:S3-S4.

    Paroxysmal nocturnal hemoglobinuria: Where are we going.
    Am J Hematol. 2023;98 Suppl 4:S33-S43.
    PubMed     Abstract available

  68. DUVAL A, Fremeaux-Bacchi V
    Complement biology for hematologists.
    Am J Hematol. 2023;98 Suppl 4:S5-S19.
    PubMed     Abstract available

  69. LEON J, LeStang MB, Sberro-Soussan R, Servais A, et al
    Complement-driven hemolytic uremic syndrome.
    Am J Hematol. 2023;98 Suppl 4:S44-S56.
    PubMed     Abstract available

  70. PANSE J
    Paroxysmal nocturnal hemoglobinuria: Where we stand.
    Am J Hematol. 2023;98 Suppl 4:S20-S32.
    PubMed     Abstract available

  71. DIAMANTOPOULOS PT, Solomou E, Symeonidis A, Pappa V, et al
    The prognostic significance of macrocytosis in patients with myelodysplastic neoplasms.
    Am J Hematol. 2023;98:E119-E122.

  72. POURDIEU C, El Hoss S, Le Roux E, Pages J, et al
    Relevance of Howell-Jolly body counts for measuring spleen function in sickle cell disease.
    Am J Hematol. 2023;98:E110-E112.

  73. GAARTMAN AE, van Tuijn CFJ, Nur E, Vogt L, et al
    The association between renal function decline and disease severity in sickle cell disease.
    Am J Hematol. 2023;98:E95-E97.

    April 2023
  74. TEFFERI A, Vannucchi AM
    JAK2 inhibitor treatment of anemia in myelofibrosis.
    Am J Hematol. 2023 Apr 21. doi: 10.1002/ajh.26934.

  75. AGGARWAL N, Manley AL, Shalhoub R, Durrani J, et al
    Alemtuzumab in relapsed immune severe aplastic anemia: Long-term results of a phase II study.
    Am J Hematol. 2023 Apr 6. doi: 10.1002/ajh.26924.
    PubMed     Abstract available

  76. ONI MO, Archer NM
    Intranasal fentanyl works-Why are we not using it more to treat acute pain in sickle cell disease?
    Am J Hematol. 2023;98:564-565.

  77. REES CA, Brousseau DC, Ahmad FA, Bennett J, et al
    Intranasal fentanyl and discharge from the emergency department among children with sickle cell disease and vaso-occlusive pain: A multicenter pediatric emergency medicine perspective.
    Am J Hematol. 2023;98:620-627.
    PubMed     Abstract available

  78. REDJOUL R, Beckerich F, de Luna G, Leclerc M, et al
    ABO blood barrier to engraftment after allogeneic stem cell transplantation in sickle cell disease: A case-story with two successive HLA-matched sibling donors.
    Am J Hematol. 2023;98:692-696.

    March 2023
  79. RISINGER M, Kim PS, Rodriguez RX, Narvaez Rivas M, et al
    Hemolytic anemia and macrothrombocytopenia: a lipid problem?
    Am J Hematol. 2023 Mar 28. doi: 10.1002/ajh.26916.

  80. RAI P, Okhomina VI, Kang G, Martinez HR, et al
    Longitudinal effect of disease-modifying therapy on left ventricular diastolic function in children with sickle cell anemia.
    Am J Hematol. 2023 Mar 8. doi: 10.1002/ajh.26911.
    PubMed     Abstract available

  81. LANSER L, Plaikner M, Schroll A, Burkert FR, et al
    Tissue iron distribution in patients with anemia of inflammation: results of a pilot study.
    Am J Hematol. 2023 Mar 7. doi: 10.1002/ajh.26909.
    PubMed     Abstract available

  82. COHEN AR
    Thalassemia enters a new age ... And more lies ahead.
    Am J Hematol. 2023;98:379-380.

  83. AL-SAMKARI H, Grace RF, Glenthoj A, Andres O, et al
    Early-onset reduced bone mineral density in patients with pyruvate kinase deficiency.
    Am J Hematol. 2023;98:E57-E60.

  84. ADESINA OO, Brunson A, Fisch SC, Yu B, et al
    Pregnancy outcomes in women with sickle cell disease in California.
    Am J Hematol. 2023;98:440-448.
    PubMed     Abstract available

  85. FORNI GL, Gianesin B, Musallam KM, Longo F, et al
    Overall and complication-free survival in a large cohort of patients with beta-thalassemia major followed over 50 years.
    Am J Hematol. 2023;98:381-387.
    PubMed     Abstract available

  86. RECCHIUTI A, Federti E, Matte A, Mazzi F, et al
    Impaired pro-resolving mechanisms promote abnormal NETosis, fueling autoimmunity in sickle cell disease.
    Am J Hematol. 2023;98:E45-E48.

    February 2023
  87. ALHOMOUD M, Soave R, Kluk MJ, Shore T, et al
    Acute Hemolytic Anemia After Hematopoietic Stem Cell Transplantation: An Unusual Invader.
    Am J Hematol. 2023 Feb 6. doi: 10.1002/ajh.26873.

  88. BAIN BJ, Myburgh J, Lund K, Chaidos A, et al
    G6PD deficiency in patients identified as female.
    Am J Hematol. 2023;98:359-360.

    January 2023
  89. GLASPY J, Gabrail NY, Locantore-Ford P, Lee T, et al
    Open-label, Phase 2 study of roxadustat for the treatment of anemia in patients receiving chemotherapy for non-myeloid malignancies.
    Am J Hematol. 2023 Jan 29. doi: 10.1002/ajh.26865.
    PubMed     Abstract available

  90. KANG HA, Barner JC, Lawson KA, Rascati K, et al
    Impact of adherence to hydroxyurea on health outcomes among patients with sickle cell disease.
    Am J Hematol. 2023;98:90-101.
    PubMed     Abstract available

  91. KANTER J, Thompson AA, Pierciey FJ Jr, Hsieh M, et al
    Lovo-cel gene therapy for sickle cell disease: Treatment process evolution and outcomes in the initial groups of the HGB-206 study.
    Am J Hematol. 2023;98:11-22.
    PubMed     Abstract available

    December 2022
  92. ZHANG Y, Zhou H, Jiang Z, Wu D, et al
    Safety and efficacy of jaktinib in the treatment of Janus kinase inhibitor-naive patients with myelofibrosis: Results of a phase II trial.
    Am J Hematol. 2022;97:1510-1519.
    PubMed     Abstract available

    November 2022
  93. SEBASTIANI P, Steinberg MH
    Fetal Hemoglobin per Erythrocyte (HbF/F-cell) After Gene Therapy for Sickle Cell Anemia.
    Am J Hematol. 2022 Nov 24. doi: 10.1002/ajh.26791.

  94. POTHAST CR, van Dijk K, Pool ES, Halkes CJM, et al
    SARS-CoV-2 mRNA vaccination of aplastic anemia patients is safe and effective.
    Am J Hematol. 2022 Nov 13. doi: 10.1002/ajh.26780.

  95. GANGAT N, Begna KH, Al-Kali A, Hogan W, et al
    Predictors of anemia response to momelotinib therapy in myelofibrosis and impact on survival.
    Am J Hematol. 2022 Nov 8. doi: 10.1002/ajh.26778.
    PubMed     Abstract available

  96. ACHEBE MO, Mandell E, Jolley K, Park HS, et al
    Pagophagia and Restless Legs Syndrome are Highly Associated with Iron Deficiency and Should Be Included in Histories Evaluating Anemia.
    Am J Hematol. 2022 Nov 2. doi: 10.1002/ajh.26775.

  97. MAIRA D, Duca L, Busti F, Consonni D, et al
    The role of hypoxia and inflammation in the regulation of iron metabolism and erythropoiesis in COVID-19: The IRONCOVID study.
    Am J Hematol. 2022;97:1404-1412.
    PubMed     Abstract available

  98. MINNITI C, Brugnara C, Steinberg MH
    HbSC disease: A time for progress.
    Am J Hematol. 2022;97:1390-1393.

  99. SISSOKO A, Fricot-Monsinjon A, Roussel C, Manceau S, et al
    Erythrocytic vacuoles that accumulate a fluorescent dye predict spleen size and function in sickle cell disease.
    Am J Hematol. 2022;97:E385-E388.

  100. REES CA, Brousseau DC, Ahmad FA, Bennett J, et al
    Adherence to NHLBI guidelines for the emergent management of vaso-occlusive episodes in children with sickle cell disease: A multicenter perspective.
    Am J Hematol. 2022;97:E412-E415.

  101. DAVID MS, Jones J, Lauriello A, Nnake I, et al
    Converting adults with sickle cell disease from full agonist opioids to buprenorphine: A reliable method with safety and early evidence of reduced acute care utilization.
    Am J Hematol. 2022;97:1435-1442.
    PubMed     Abstract available

    October 2022
  102. DI MODICA SM, Tanzi E, Olivari V, Lidonnici MR, et al
    Transferrin receptor 2 (Tfr2) genetic deletion makes transfusion-independent a murine model of transfusion-dependent beta-thalassemia.
    Am J Hematol. 2022;97:1324-1336.
    PubMed     Abstract available

  103. MKOMBACHEPA M, Khamis B, Rwegasira G, Urio F, et al
    High incidence of malaria in patients with sickle cell disease.
    Am J Hematol. 2022;97:E380-E381.

  104. GIBSON SJ, Kalfa TA, DeStefano CB
    Insane in the membrane: A case of hereditary spherocytic pyropoikilocytosis.
    Am J Hematol. 2022;97:1384-1385.

  105. LEWIS J, Greenway SC, Khan F, Singh G, et al
    Assessment of donor cell engraftment after hematopoietic stem cell transplantation for sickle cell disease: A review of current and future methods.
    Am J Hematol. 2022;97:1359-1371.
    PubMed     Abstract available

    September 2022
  106. MORIS W, Koek GH, van Deursen CTBM
    A comment on: "Proton pump inhibition for secondary hemochromatosis in hereditary anemia: a phase III placebo-controlled randomized cross-over clinical trial".
    Am J Hematol. 2022 Sep 23. doi: 10.1002/ajh.26740.

  107. DHEDIN N, Chevillon F, Castelle M, Lavoipiere V, et al
    HLA-matched related donor hematopoietic stem cell transplantation is a suitable treatment in adolescents and adults with sickle cell disease: Comparison of myeloablative and non-myeloablative approaches.
    Am J Hematol. 2022;97:E359-E362.

  108. PORTELA GT, Butters MA, Brooks MM, Candra L, et al
    Comprehensive assessment of cognitive function in adults with moderate and severe sickle cell disease.
    Am J Hematol. 2022;97:E344-E346.

    August 2022
  109. BHUTANI G, Leung N, Said SM, Valeri AM, et al
    The Prevalence and Clinical Outcomes of Microangiopathic Hemolytic Anemia in Patients with Biopsy Proven Renal Thrombotic Microangiopathy.
    Am J Hematol. 2022 Aug 28. doi: 10.1002/ajh.26705.
    PubMed     Abstract available

  110. NARDO-MARINO A, Glenthoj A, Brewin JN, Petersen J, et al
    The significance of spleen size in children with sickle cell anemia.
    Am J Hematol. 2022 Aug 28. doi: 10.1002/ajh.26703.
    PubMed     Abstract available

  111. WAHEED A, Kuter DJ
    Hematological support of patients with significant anemia who decline red blood cell blood transfusion.
    Am J Hematol. 2022 Aug 28. doi: 10.1002/ajh.26701.

  112. SZEPETOWSKI S, Berger C, Joly P, Baron-Joly S, et al
    Homozygosity for the hyperunstable hemoglobin variant Hb Agrinio (HBA2:c.89T>C) leads to severe antenatal anemia: Eight new cases in three families.
    Am J Hematol. 2022 Aug 12. doi: 10.1002/ajh.26687.

  113. NAGALAPURAM V, Kanter J
    Multi-organ dysfunction secondary to abrupt discontinuation of voxelotor in a patient with severe sickle cell disease.
    Am J Hematol. 2022;97:E318-E320.

  114. GRAF M, Tuly R, Gallagher M, Sullivan J, et al
    Value of a cure for sickle cell disease in reducing economic disparities.
    Am J Hematol. 2022;97:E289-E291.

  115. LE MONNIER O, Joseph L, Bodard S, Boudhabhay I, et al
    Hepato-splenic abscesses in a sickle cell disease patient.
    Am J Hematol. 2022;97:1118-1119.

  116. LAI YR, Cappellini MD, Aydinok Y, Porter J, et al
    An open-label, multicenter, efficacy, and safety study of deferasirox in iron-overloaded patients with non-transfusion-dependent thalassemia (THETIS): 5-year results.
    Am J Hematol. 2022;97:E281-E284.

  117. MANSOUR-HENDILI L, Flamarion E, Michel M, Morbieu C, et al
    Acquired spherocytosis due to somatic ANK1 mutations as a manifestation of clonal hematopoiesis in elderly patients.
    Am J Hematol. 2022;97:E285-E288.

  118. OSUNKWO I, James J, El-Rassi F, Nero A, et al
    Burden of disease, treatment utilization, and the impact on education and employment in patients with sickle cell disease: A comparative analysis of high- and low- to middle-income countries for the international Sickle Cell World Assessment Survey.
    Am J Hematol. 2022;97:1055-1064.
    PubMed     Abstract available

    July 2022
  119. POUCHELON C, Lafont C, Lafarge A, Comont T, et al
    Characteristics and Outcome of Adults With Severe Autoimmune Hemolytic Anemia Admitted to the Intensive Care Unit: Results From A Large French Observational Study.
    Am J Hematol. 2022 Jul 24. doi: 10.1002/ajh.26665.

  120. KARKOSKA K, Pfeiffer A, Beebe DW, Quinn CT, et al
    Early hydroxyurea use is neuroprotective in children with sickle cell anemia.
    Am J Hematol. 2022 Jul 14. doi: 10.1002/ajh.26664.

  121. MINETTI G, Bogdanova AY, Mairbaurl H, Kaestner L, et al
    Space anemia unexplained: Red blood cells seem to be space-proof.
    Am J Hematol. 2022 Jul 14. doi: 10.1002/ajh.26663.

  122. KRALOVA B, Sochorcova L, Song J, Jahoda O, et al
    Developmental changes in iron metabolism and erythropoiesis in mice with human gain-of-function erythropoietin receptor.
    Am J Hematol. 2022 Jul 11. doi: 10.1002/ajh.26658.
    PubMed     Abstract available

  123. XIAOHUA L, Liu Y, Qu C, Mol B, et al
    The association of iron deficiency anemia, thrombocytosis at delivery and postpartum venous thromboembolism.
    Am J Hematol. 2022 Jul 9. doi: 10.1002/ajh.26657.

  124. BREWIN JN, Nardo-Marino A, Stuart-Smith S, El Hoss S, et al
    The pleiotropic effects of alpha thalassemia on HbSS and HbSC sickle cell disease: reduced erythrocyte cation co-transport activity, serum erythropoietin, and transfusion burden, do not translate into increased survival.
    Am J Hematol. 2022 Jul 8. doi: 10.1002/ajh.26652.
    PubMed     Abstract available

  125. WESTIN ER, Tsao DS, Atay O, Landry BP, et al
    Validation of single-gene noninvasive prenatal testing for sickle cell disease.
    Am J Hematol. 2022;97:E270-E273.

  126. DE LUNA G, Habibi A, Odievre MH, Guillet H, et al
    Blood exchange transfusion with dexamethasone and Tocilizumab for management of hospitalized patients with sickle cell disease and severe COVID-19: Preliminary evaluation of a novel algorithm.
    Am J Hematol. 2022;97:E260-E264.

  127. VITTAL A, Alao H, Hercun J, Sharma B, et al
    Safety of liver biopsy in patients with sickle cell related liver disease: A single-center experience.
    Am J Hematol. 2022;97:E257-E260.

  128. VAN DIJK MJ, Rab MAE, van Oirschot BA, Bos J, et al
    Safety and efficacy of mitapivat, an oral pyruvate kinase activator, in sickle cell disease: A phase 2, open-label study.
    Am J Hematol. 2022;97:E226-E229.

  129. WONG KH, Soffer GK
    Characteristics and prevalence of antibiotic allergies in patients with sickle cell disease: A single-center retrospective study.
    Am J Hematol. 2022;97:E247-E249.

  130. GIANNOTTA JA, Fattizzo B, Bortolotti M, Girmenia C, et al
    SARS-CoV-2 vaccination in patients with paroxysmal nocturnal hemoglobinuria: An Italian multicenter survey.
    Am J Hematol. 2022;97:E229-E232.

    June 2022
  131. KOURY MJ, Agarwal R, Chertow GM, Eckardt KU, et al
    Erythropoietic effects of vadadustat in patients with anemia associated with chronic kidney disease.
    Am J Hematol. 2022 Jun 25. doi: 10.1002/ajh.26644.
    PubMed     Abstract available

  132. BAIN BJ, Myburgh J, Hann A, Layton DM, et al
    Voxelotor in sickle cell disease.
    Am J Hematol. 2022;97:830-832.

  133. YOUNG DJ, Fan X, Groarke EM, Patel B, et al
    Long-term eltrombopag for bone marrow failure depletes iron.
    Am J Hematol. 2022;97:791-801.
    PubMed     Abstract available

    May 2022
  134. KRONER BL, Hankins JS, Pugh N, Kutlar A, et al
    Pregnancy outcomes with hydroxyurea use in women with sickle cell disease.
    Am J Hematol. 2022;97:603-612.
    PubMed     Abstract available

    April 2022
  135. VAN VUREN A, Kerkhoffs JL, Schols S, Rijneveld A, et al
    Proton pump inhibition for secondary hemochromatosis in hereditary anemia: a phase III placebo-controlled randomized cross-over clinical trial. NIH.
    Am J Hematol. 2022 Apr 26. doi: 10.1002/ajh.26581.
    PubMed     Abstract available

  136. NAAMI N, Borkhardt A, Yoshimi A, Grinstein L, et al
    13-month-old girl with hyporegenerative macrocytic anemia due to Brown-Vialetto-Van Laere syndrome 2.
    Am J Hematol. 2022 Apr 20. doi: 10.1002/ajh.26573.

  137. PLESSIER A, Esposito-Farese M, Baiges A, Shukla A, et al
    Paroxysmal nocturnal hemoglobinuria and vascular liver disease: Eculizumab therapy decreases mortality and thrombotic complications.
    Am J Hematol. 2022;97:431-439.
    PubMed     Abstract available

  138. AYGUN B, Bello A, Thompson AA, Davis L, et al
    Clinical phenotypes of three children with sickle cell disease caused by HbS/Sicilian (deltabeta)(0) -thalassemia deletion.
    Am J Hematol. 2022;97:E156-E158.

  139. SIVAGURU G, Simini G, Bain BJ
    Persistent neonatal jaundice resulting from hereditary pyropoikilocytosis.
    Am J Hematol. 2022;97:506-507.

    March 2022
  140. ARLET JB, Lionnet F, Khimoud D, Joseph L, et al
    Risk factors for severe COVID-19 in hospitalized sickle cell disease patients: A study of 319 patients in France.
    Am J Hematol. 2022;97:E86-E91.

  141. SCHWARTZ JD, Barcellini W, Grace RF, Bianchi P, et al
    Who should be eligible for gene therapy clinical trials in red blood cell pyruvate kinase deficiency (PKD)?: Toward an expanded definition of severe PKD.
    Am J Hematol. 2022;97:E120-E125.

  142. CURTIS SA, Betancourt J, Kottapalli N, Campbell S, et al
    Voxelotor use in adults with sickle cell disease in a real-world setting.
    Am J Hematol. 2022;97:E125-E128.

  143. BRADFORD C, Miodownik H, Thomas M, Ogu UO, et al
    Patient-focused inquiry on hydroxyurea therapy adherence and reasons for discontinuation in adults with sickle cell disease.
    Am J Hematol. 2022;97:E93-E95.

  144. ALLALI S, Chhun S, de Montalembert M, Heilbronner C, et al
    Tocilizumab for severe acute chest syndrome in a child with sickle cell disease and dramatically high interleukin-6 values in endotracheal and pleural fluids.
    Am J Hematol. 2022;97:E81-E83.

    February 2022
  145. KUTER DJ, Rogers KA, Boxer MA, Choi M, et al
    Fostamatinib for the treatment of warm antibody autoimmune hemolytic anemia: Phase 2, multicenter, open-label study.
    Am J Hematol. 2022 Feb 18. doi: 10.1002/ajh.26508.
    PubMed     Abstract available

  146. OLUPOT-OLUPOT P, Connon R, Kiguli S, Opoka RO, et al
    A predictive algorithm for identifying children with sickle cell anemia among children admitted to hospital with severe anemia in Africa.
    Am J Hematol. 2022 Feb 11. doi: 10.1002/ajh.26492.
    PubMed     Abstract available

  147. FIELDS ME, Mirro AE, Binkley MM, Guilliams KP, et al
    Cerebral Oxygen Metabolic Stress is Increased in Children with Sickle Cell Anemia Compared to Anemic Controls.
    Am J Hematol. 2022 Feb 3. doi: 10.1002/ajh.26485.
    PubMed     Abstract available

  148. ANGELI AM, Megna B, Mazepa M, Ivy ZK, et al
    Transfusion-Dependent Anemia Secondary to Vitamin C Deficiency.
    Am J Hematol. 2022 Feb 2. doi: 10.1002/ajh.26484.

  149. LONGO F, Gianesin B, Voi V, Motta I, et al
    Italian patients with hemoglobinopathies exhibit a 5-fold increase in age-standardized lethality due to SARS-CoV-2 infection.
    Am J Hematol. 2022;97:E75-E78.

  150. PATNAIK MM, Santini V
    Targeting ineffective hematopoiesis in myelodysplastic syndromes.
    Am J Hematol. 2022;97:171-173.

  151. ANDOLFO I, Alper SL, Iolascon A
    Nobel prize in physiology or medicine 2021, receptors for temperature and touch: Implications for hematology.
    Am J Hematol. 2022;97:168-170.

  152. TVEDT THA, Steien E, Ovrebo B, Haaverstad R, et al
    Sutimlimab, an investigational C1s inhibitor, effectively prevents exacerbation of hemolytic anemia in a patient with cold agglutinin disease undergoing major surgery.
    Am J Hematol. 2022;97:E51-E54.

    January 2022
  153. CHIN-YEE B, Cheong I, Matyashin M, Lazo-Langner A, et al
    Serum erythropoietin levels in 696 patients investigated for erythrocytosis with JAK2 mutation analysis.
    Am J Hematol. 2022 Jan 19. doi: 10.1002/ajh.26471.

  154. DORES GM, Nayernama A, Cheng C, Moureaud C, et al
    Hemolytic anemia following alectinib reported to the U.S. Food and Drug Administration Adverse Event Reporting System.
    Am J Hematol. 2022 Jan 5. doi: 10.1002/ajh.26454.

  155. FEJTKOVA M, Sukova M, Hlozkova K, Skvarova Kramarzova K, et al
    TLR8/TLR7 dysregulation due to a novel TLR8 mutation causes severe autoimmune hemolytic anemia and autoinflammation in identical twins.
    Am J Hematol. 2022 Jan 3. doi: 10.1002/ajh.26452.
    PubMed     Abstract available

  156. RIBEIL JA
    Primary myelofibrosis in untreated sickle cell disease: Are adult patients at higher risk for developing hematological myeloid neoplasms?
    Am J Hematol. 2022;97:4-6.

  157. REYES LZ, Figueroa J, Leake D, Khemani K, et al
    Safety of intravenous arginine therapy in children with sickle cell disease hospitalized for vaso-occlusive pain: A randomized placebo-controlled trial in progress.
    Am J Hematol. 2022;97:E21-E24.

  158. FORD AL, Hsu HC, Binkley MM, Rogers S, et al
    Probing single-cell oxygen reserve in sickled erythrocytes via in vivo photoacoustic microscopy.
    Am J Hematol. 2022;97:E11-E14.

  159. GREEN SE, Singh ZN, Baer MR
    Primary myelofibrosis in a patient with sickle cell disease.
    Am J Hematol. 2022;97:160-161.

    December 2021
  160. RUIZ MA, Shah BN, Ren G, Shuey D, et al
    Thrombomodulin and Multi-Organ Failure in Sickle Cell Anemia.
    Am J Hematol. 2021 Dec 20. doi: 10.1002/ajh.26443.

  161. MUSALLAM KM, Vitrano A, Meloni A, Addario Pollina S, et al
    Risk of mortality from anemia and iron overload in non-transfusion-dependent beta-thalassemia.
    Am J Hematol. 2021 Dec 4. doi: 10.1002/ajh.26428.

  162. JOHNSON S, Gordeuk VR, Machado R, Gibbs JSR, et al
    Exercise-induced changes of vital signs in adults with sickle cell disease.
    Am J Hematol. 2021;96:1630-1638.
    PubMed     Abstract available

    November 2021
  163. GERBER GF, DeZern AE, Chaturvedi S, Brodsky RA, et al
    A 15-year, single institution experience of anticoagulation management in paroxysmal nocturnal hemoglobinuria patients on terminal complement inhibition with history of thromboembolism.
    Am J Hematol. 2021 Nov 20. doi: 10.1002/ajh.26414.

  164. FATTIZZO B, Giannotta JA, Cecchi N, Barcellini W, et al
    SARS-CoV-2 vaccination in patients with autoimmune cytopenias: The experience of a reference center.
    Am J Hematol. 2021;96:E413-E416.

  165. HENRY DH, Glaspy J, Harrup R, Mittelman M, et al
    Roxadustat for the Treatment of Anemia in Patients with Lower-Risk Myelodysplastic Syndrome: Open-label, Dose-selection, Lead-in Stage of a Phase 3 Study.
    Am J Hematol. 2021 Nov 1. doi: 10.1002/ajh.26397.
    PubMed     Abstract available

  166. KOUNTOURIS P, Stephanou C, Archer N, Bonifazi F, et al
    The International Hemoglobinopathy Research Network (INHERENT): An international initiative to study the role of genetic modifiers in hemoglobinopathies.
    Am J Hematol. 2021;96:E416-E420.

  167. MARTIN ES, Ferrer A, Mangaonkar AA, Khan SP, et al
    Spectrum of hematological malignancies, clonal evolution and outcomes in 144 Mayo Clinic patients with germline predisposition syndromes.
    Am J Hematol. 2021;96:1450-1460.
    PubMed     Abstract available

  168. LONGORIA JN, Pugh NL, Gordeuk V, Hsu LL, et al
    Patient-reported neurocognitive symptoms influence instrumental activities of daily living in sickle cell disease.
    Am J Hematol. 2021;96:1396-1406.
    PubMed     Abstract available

  169. MUSALLAM KM, Bou-Fakhredin R, Cappellini MD, Taher AT, et al
    2021 update on clinical trials in beta-thalassemia.
    Am J Hematol. 2021;96:1518-1531.
    PubMed     Abstract available

  170. HEBBEL RP, Vercellotti GM
    Multiple inducers of endothelial NOS (eNOS) dysfunction in sickle cell disease.
    Am J Hematol. 2021;96:1505-1517.
    PubMed     Abstract available

    October 2021
  171. MAKHARADZE T, Boccia R, Krupa A, Blackman N, et al
    Efficacy and Safety of Ferric Carboxymaltose Infusion in Reducing Anemia in Patients Receiving Chemotherapy for Nonmyeloid Malignancies: a Randomized, Placebo-Controlled Study (IRON CLAD).
    Am J Hematol. 2021 Oct 15. doi: 10.1002/ajh.26376.
    PubMed     Abstract available

  172. COX HD, Miller GD, Manandhar A, Husk JD, et al
    Tracking immature reticulocyte proteins for improved detection of recombinant human erythropoietin (rhEPO) abuse.
    Am J Hematol. 2021 Oct 9. doi: 10.1002/ajh.26368.
    PubMed     Abstract available

  173. ASPERTI M, Brilli E, Denardo A, Gryzik M, et al
    Iron distribution in different tissues of homozygous Mask (msk/msk) mice and the effects of oral iron treatments.
    Am J Hematol. 2021;96:1253-1263.
    PubMed     Abstract available

  174. DE MONTALEMBERT M, Voskaridou E, Oevermann L, Cannas G, et al
    Real-Life experience with hydroxyurea in patients with sickle cell disease: Results from the prospective ESCORT-HU cohort study.
    Am J Hematol. 2021;96:1223-1231.
    PubMed     Abstract available

  175. PIATTI G, Giuditta M, Pierini A, Consonni D, et al
    Muscular de-conditioning and reduced cardiac inotropism due to iron deposition reduce exercise tolerance in beta thalassemia major.
    Am J Hematol. 2021;96:E370-E373.

    September 2021
  176. VIRK ZM, Patel AA, Leaf RK, Al-Samkari H, et al
    Predictors of Mortality and Outcomes of Liver Transplant in Spur Cell Hemolytic Anemia.
    Am J Hematol. 2021 Sep 22. doi: 10.1002/ajh.26359.
    PubMed     Abstract available

  177. PETIT AF, Kulasekararaj AG, Eikema DJ, Maschan A, et al
    Upfront unrelated donor Hematopoietic stem cell transplantation in patients with idiopathic aplastic anemia: a retrospective study of the Severe Aplastic Anemia Working Party of European Bone Marrow Transplantation.
    Am J Hematol. 2021 Sep 22. doi: 10.1002/ajh.26354.

  178. MEZNARICH JA, Rets A, Agarwal AM, Christensen RD, et al
    Novel, De Novo, Beta-Globin Variant with Decreased Oxygen Affinity (HBB:C.317T>A, "Hemoglobin St. George") in a Healthy Child with Low Oxygen Saturations and Anemia.
    Am J Hematol. 2021 Sep 22. doi: 10.1002/ajh.26356.

  179. YE L, Jing L, Guo J, Zhao X, et al
    Red Blood Cell Lifespan is Reduced in Severe Aplastic Anemia and Improves with Response to Immunosuppressive Treatment.
    Am J Hematol. 2021 Sep 2. doi: 10.1002/ajh.26344.

  180. D'HUMIERES T, Savale L, Inamo J, Deux JF, et al
    Cardiovascular phenotypes predict clinical outcomes in sickle cell disease: An echocardiography-based cluster analysis.
    Am J Hematol. 2021;96:1166-1175.
    PubMed     Abstract available

  181. ROGER C, Lionnet F, Mattioni S, Livrozet M, et al
    Risk factors for CKD stage II onset in a prospective cohort of homozygous sickle cell adults.
    Am J Hematol. 2021;96:1147-1155.
    PubMed     Abstract available

  182. MANSOUR-HENDILI L, Egee S, Monedero-Alonso D, Bouyer G, et al
    Multiple thrombosis in a patient with Gardos channelopathy and a new KCNN4 mutation.
    Am J Hematol. 2021;96:E318-E321.

  183. VAN VUREN AJ, Minniti CP, Mendelsohn L, Baird JH, et al
    Lactate dehydrogenase to carboxyhemoglobin ratio as a biomarker of heme release to heme processing is associated with higher tricuspid regurgitant jet velocity and early death in sickle cell disease.
    Am J Hematol. 2021;96:E315-E318.

    August 2021
  184. PEREZ BOTERO J, Reese JA, George JN, McIntosh JJ, et al
    Severe Thrombocytopenia and Microangiopathic Hemolytic Anemia in Pregnancy: A Guide for the Consulting Hematologist.
    Am J Hematol. 2021 Aug 23. doi: 10.1002/ajh.26328.
    PubMed     Abstract available

  185. DEXTER D, Layton DM, Kiritkumar K, Bain BJ, et al
    Peripheral blood features of iron overload in post-splenectomy, type I congenital dyserythropoietic anemia.
    Am J Hematol. 2021 Aug 20. doi: 10.1002/ajh.26327.

  186. SHIMANO KA, Narla A, Rose MJ, Gloude NJ, et al
    Diagnostic work-up for severe aplastic anemia in children: Consensus of the North American Pediatric Aplastic Anemia Consortium.
    Am J Hematol. 2021 Aug 3. doi: 10.1002/ajh.26310.
    PubMed     Abstract available

  187. PEREZ-LAMAS L, Moreno-Jimenez G, Tenorio-Nunez MC, Velazquez-Kennedy K, et al
    Hemolytic crisis due to Covid-19 vaccination in a woman with cold agglutinin disease.
    Am J Hematol. 2021;96:E288-E291.

  188. BOU-FAKHREDIN R, Daadaa H, Koussa S, Abou Nasr T, et al
    SARS-CoV-2 infection in patients with beta-thalassemia: Experience from Lebanon.
    Am J Hematol. 2021;96:E285-E288.

  189. HAYFRON-BENJAMIN CF, Asare EV, Boafor T, Olayemi E, et al
    Low FEV1 is associated with fetal death in pregnant women with sickle cell disease.
    Am J Hematol. 2021;96:E303-E306.

  190. EDJLALI M, Gobin-Metteil MP, Mele N, Maier B, et al
    Transcranial color-coded duplex sonography reliably identifies intracranial vasculopathy in adult patients with sickle cell disease.
    Am J Hematol. 2021;96:961-967.
    PubMed     Abstract available

  191. VU C, Bush A, Choi S, Borzage M, et al
    Reduced global cerebral oxygen metabolic rate in sickle cell disease and chronic anemias.
    Am J Hematol. 2021;96:901-913.
    PubMed     Abstract available

  192. KNEE KM, Jasuja R, Barakat A, Rao D, et al
    PF-07059013: A non-covalent hemoglobin modulator favorably impacts disease state in a mouse model of sickle cell disease.
    Am J Hematol. 2021;96:E272-E275.

  193. MALECKA A, Troen G, Delabie J, Malecki J, et al
    The mutational landscape of cold agglutinin disease: CARD11 and CXCR4 mutations are correlated with lower hemoglobin levels.
    Am J Hematol. 2021;96:E279-E283.

  194. JANKOVSKY N, Caulier A, Demagny J, Guitton C, et al
    Recent advances in the pathophysiology of PIEZO1-related hereditary xerocytosis.
    Am J Hematol. 2021;96:1017-1026.
    PubMed     Abstract available

  195. FAN BE, Cao L, Gallardo CA, Lee SMS, et al
    Myeloid and lymphoid vacuolation in VEXAS syndrome.
    Am J Hematol. 2021;96:1056-1057.

    July 2021
  196. HANSEN DL, Berentsen S, Fattizzo B, Hansen PL, et al
    Seasonal variation in the incidence of cold agglutinin disease in Norway, Denmark, and Italy.
    Am J Hematol. 2021;96:E262-E265.

  197. WAHEED A, Kuter DJ
    Iron overload after complement inhibitor treatment of Paroxysmal Nocturnal Hemoglobinuria.
    Am J Hematol. 2021;96:E235-E237.

  198. MONTALBAN-BRAVO G, Kanagal-Shamanna R, Darbaniyan F, Siddiqui MT, et al
    Clinical, genomic, and transcriptomic differences between myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) and myelodysplastic syndrome with ring sideroblasts (MDS-RS).
    Am J Hematol. 2021;96:E246-E249.

  199. KULASEKARARAJ AG, Brodsky RA, Hill A
    Monitoring of patients with paroxysmal nocturnal hemoglobinuria on a complement inhibitor.
    Am J Hematol. 2021;96:E232-E235.

    June 2021
  200. GURUNG K, Bain BJ
    A normal mean cell volume does not exclude a diagnosis of megaloblastic anemia.
    Am J Hematol. 2021 Jun 24. doi: 10.1002/ajh.26283.

  201. KIRK SE, Scheurer ME, Bernhardt MB, Mahoney DH, et al
    Phosphorus levels in children treated with intravenous ferric carboxymaltose.
    Am J Hematol. 2021;96:E215-E218.

  202. PANAGIOTA V, Meggendorfer M, Kubasch AS, Gabdoulline R, et al
    Impact of PPM1D mutations in patients with myelodysplastic syndrome and deletion of chromosome 5q.
    Am J Hematol. 2021;96:E207-E210.

  203. ZHANG X, Yang Y, Zhang H, Du Z, et al
    A rare complex rearrangement in the beta-globin gene cluster causing a novel homozygous (G) gamma((A) gammadeltabeta)(0) -thalassemia.
    Am J Hematol. 2021;96:E189-E193.

    May 2021
  204. RAMIREZ MJ, Pujol R, Trujillo-Quintero JP, Minguillon J, et al
    Natural gene therapy by reverse mosaicism leads to improved hematology in Fanconi anemia patients.
    Am J Hematol. 2021 May 13. doi: 10.1002/ajh.26234.
    PubMed     Abstract available

  205. KIM SJ, Song J, Reading NS, Lautersztain J, et al
    Novel mechanism of hereditary pyropoikilocytosis phenotype due to co-inheritance of beta globin and alpha spectrin mutations.
    Am J Hematol. 2021;96:E150-E154.

  206. KALANTAR-ZADEH K, Ganz T, Trumbo H, Seid MH, et al
    Parenteral iron therapy and phosphorus homeostasis: A review.
    Am J Hematol. 2021;96:606-616.
    PubMed     Abstract available

  207. BAIN BJ
    Alpha chain inclusions in peripheral blood erythroblasts and erythrocytes.
    Am J Hematol. 2021;96:630-631.

    April 2021
  208. MAQUET J, Lafaurie M, Walter O, Sailler L, et al
    Epidemiology of autoimmune hemolytic anemia: a nationwide population-based study in France.
    Am J Hematol. 2021 Apr 30. doi: 10.1002/ajh.26213.

  209. BARCELLINI W, Zaninoni A, Giannotta JA, Merati G, et al
    Circulating extracellular vesicles and cytokines in congenital and acquired hemolytic anemias.
    Am J Hematol. 2021;96:E129-E132.

  210. MINNITI CP, Knight-Madden J, Tonda M, Gray S, et al
    The impact of voxelotor treatment on leg ulcers in patients with sickle cell disease.
    Am J Hematol. 2021;96:E126-E128.

  211. AL-ALI AK, Alsulaiman A, Alfarhan M, Safaya S, et al
    Sickle cell disease in the Eastern Province of Saudi Arabia: Clinical and laboratory features.
    Am J Hematol. 2021;96:E117-E121.

  212. MCGRATH M, Quint EH, Weyand AC
    Depression in adolescents and young adults with heavy menstrual bleeding in a referral clinic setting.
    Am J Hematol. 2021;96:E105-E108.

  213. ARCHULETA J, van der Graaf M, Kaptein FHJ, Althaus L, et al
    Sudden death due to massive bone marrow sequestration crisis in a patient with sickle cell disease.
    Am J Hematol. 2021;96:E100-E102.

  214. OSUNKWO I, Andemariam B, Minniti CP, Inusa BPD, et al
    Impact of sickle cell disease on patients' daily lives, symptoms reported, and disease management strategies: Results from the international Sickle Cell World Assessment Survey (SWAY).
    Am J Hematol. 2021;96:404-417.
    PubMed     Abstract available

  215. LANZKRON S, Smith-Whitley K
    Swaying sickle cell research forward in support of patient reported outcomes.
    Am J Hematol. 2021;96:402-403.

    March 2021
  216. PATNAIK MM, Tefferi A
    Myelodysplastic syndromes with ring sideroblasts (MDS-RS) and MDS/myeloproliferative neoplasm with RS and thrombocytosis (MDS/MPN-RS-T) - "2021 update on diagnosis, risk-stratification, and management".
    Am J Hematol. 2021;96:379-394.
    PubMed     Abstract available

  217. DENTON CC, Shah P, Suriany S, Liu H, et al
    Loss of alpha-globin genes in human subjects is associated with improved nitric oxide-mediated vascular perfusion.
    Am J Hematol. 2021;96:277-281.
    PubMed     Abstract available

  218. MUSALLAM KM, Rivella S, Taher AT
    Management of non-transfusion-dependent beta-thalassemia (NTDT): The next 5 years.
    Am J Hematol. 2021;96:E57-E59.

    February 2021
  219. ZUBICARAY J, Pagliara D, Sevilla J, Eikema DJ, et al
    Haplo-identical or mismatched unrelated donor hematopoietic cell transplantation for Fanconi anemia: results from the Severe Aplastic Anemia Working Party of the EBMT.
    Am J Hematol. 2021 Feb 19. doi: 10.1002/ajh.26135.
    PubMed     Abstract available

  220. ROMANA M, Reminy K, Moeckesch B, Charlot K, et al
    Loss of alpha globin genes is associated with improved microvascular function in patients with sickle cell anemia.
    Am J Hematol. 2021 Feb 13. doi: 10.1002/ajh.26126.

  221. AUERBACH M, Henry D, DeLoughery TG
    Intravenous ferric derisomaltose for the treatment of iron deficiency anemia.
    Am J Hematol. 2021 Feb 13. doi: 10.1002/ajh.26124.
    PubMed     Abstract available

  222. KARKOSKA K, Quinn CT, Niss O, Pfeiffer A, et al
    Hydroyxurea improves cerebral oxygen saturation in children with sickle cell anemia.
    Am J Hematol. 2021 Feb 3. doi: 10.1002/ajh.26120.
    PubMed     Abstract available

  223. LEBENSBURGER JD, Aban I, Hilliard LM, Feig DI, et al
    Hyperuricemia and Abnormal Nocturnal Dipping Impact Glomerular Filtration Rate in Patients with Sickle Cell Anemia.
    Am J Hematol. 2021 Feb 1. doi: 10.1002/ajh.26115.

  224. MUSALLAM KM, Cappellini MD, Viprakasit V, Kattamis A, et al
    Revisiting the non-transfusion-dependent (NTDT) vs. transfusion-dependent (TDT) thalassemia classification 10 years later.
    Am J Hematol. 2021;96:E54-E56.

  225. SCHMIDT PJ, Fitzgerald K, Butler JS, Fleming MD, et al
    Global loss of Tfr2 with concomitant induced iron deficiency greatly ameliorates the phenotype of a murine thalassemia intermedia model.
    Am J Hematol. 2021;96:251-257.
    PubMed     Abstract available

    January 2021
  226. LUNATI A, Petit A, Lapillonne H, Gameiro C, et al
    VPS4A mutation in syndromic congenital hemolytic anemia without obvious signs of dyserythropoiesis.
    Am J Hematol. 2021 Jan 18. doi: 10.1002/ajh.26099.

  227. GLADWIN MT, Kato GJ, Gordeuk VR
    Identifying adolescent and young adult patients with sickle cell disease at highest risk of death.
    Am J Hematol. 2021;96:9-11.

  228. RAB MAE, Kanne CK, Bos J, van Oirschot BA, et al
    Oxygen gradient ektacytometry-derived biomarkers are associated with vaso-occlusive crises and correlate with treatment response in sickle cell disease.
    Am J Hematol. 2021;96:E29-E32.

  229. ROSANWO TO, Kean LS, Archer NM
    End the pain: Start with antiracism.
    Am J Hematol. 2021;96:4-6.

  230. OGU UO, Thomas M, Chan F, Vattappally L, et al
    L-glutamine use in adults with sickle cell disease: Clinical trials where success meets reality.
    Am J Hematol. 2021;96:E38-E40.

  231. CHALACHEVA P, Ji Y, Rosen CL, DeBaun MR, et al
    Nocturnal peripheral vasoconstriction predicts the frequency of severe acute pain episodes in children with sickle cell disease.
    Am J Hematol. 2021;96:60-68.
    PubMed     Abstract available

  232. COSTA E, Tibalinda P, Sterzi E, Leufkens HMG, et al
    Making hydroxyurea affordable for sickle cell disease in Tanzania is essential (HASTE): How to meet major health needs at a reasonable cost.
    Am J Hematol. 2021;96:E2-E5.

  233. SHAH P, Suriany S, Kato R, Bush AM, et al
    Tricuspid regurgitant jet velocity and myocardial tissue Doppler parameters predict mortality in a cohort of patients with sickle cell disease spanning from pediatric to adult age groups - revisiting this controversial concept after 16 years of additi
    Am J Hematol. 2021;96:31-39.
    PubMed     Abstract available

    December 2020
  234. KARKOSKA K, Quinn CT, Clapp K, McGann PT, et al
    Severe infusion-related reaction to crizanlizumab in an adolescent with sickle cell disease.
    Am J Hematol. 2020;95:E338-E339.

  235. COHEN J, Khudanyan A, Lu J, Wing J, et al
    A multicenter study evaluating the effectiveness and safety of single-dose low molecular weight iron dextran vs single-dose ferumoxytol for the treatment of iron deficiency.
    Am J Hematol. 2020;95:1572-1577.
    PubMed     Abstract available

    November 2020
  236. DAVIS BH
    Assay for "fetal hemoglobin levels" in erythrocytes: Impact of new In Vitro Diagnostics regulation and expanded applications in sickle cell disease management.
    Am J Hematol. 2020;95:1230-1232.

    Can any new thalassemia therapy achieve a better than 97.4% cure rate?
    Am J Hematol. 2020;95:1233-1234.

  238. HE Y, Jiang H, Li C, Zhu Y, et al
    Long-term results of the NF-08-TM protocol in stem cell transplant for patients with thalassemia major: A multi-center large-sample study.
    Am J Hematol. 2020;95:E297-E299.

  239. RUSSO R, Marra R, Andolfo I, Manna F, et al
    Uridine treatment normalizes the congenital dyserythropoietic anemia type II-like hematological phenotype in a patient with homozygous mutation in the CAD gene.
    Am J Hematol. 2020;95:1423-1426.

  240. MERLET AN, Feasson L, Bartolucci P, Hourde C, et al
    Muscle structural, energetic and functional benefits of endurance exercise training in sickle cell disease.
    Am J Hematol. 2020;95:1257-1268.
    PubMed     Abstract available

  241. HEBERT N, Rakotoson MG, Bodivit G, Audureau E, et al
    Individual red blood cell fetal hemoglobin quantification allows to determine protective thresholds in sickle cell disease.
    Am J Hematol. 2020;95:1235-1245.
    PubMed     Abstract available

  242. KUCUKAL E, Man Y, Hill A, Liu S, et al
    Whole blood viscosity and red blood cell adhesion: Potential biomarkers for targeted and curative therapies in sickle cell disease.
    Am J Hematol. 2020;95:1246-1256.
    PubMed     Abstract available

  243. DE CASTRO C, Grossi F, Weitz IC, Maciejewski J, et al
    C3 inhibition with pegcetacoplan in subjects with paroxysmal nocturnal hemoglobinuria treated with eculizumab.
    Am J Hematol. 2020;95:1334-1343.
    PubMed     Abstract available

    October 2020
  244. POLLYEA DA, Pratz K, Letai A, Jonas BA, et al
    Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: long term follow-up from a Phase 1b study.
    Am J Hematol. 2020 Oct 29. doi: 10.1002/ajh.26039.
    PubMed     Abstract available

  245. ONALO R, Cooper P, Cilliers A, Vorster BC, et al
    Randomized Control Trial of Oral Arginine Therapy for Children with Sickle Cell Anemia Hospitalized for Pain in Nigeria.
    Am J Hematol. 2020 Oct 19. doi: 10.1002/ajh.26028.
    PubMed     Abstract available

  246. WOLF M, Auerbach M, Kalra PA, Glaspy J, et al
    Safety of ferric derisomaltose and iron sucrose in patients with iron deficiency anemia: The FERWON-IDA/NEPHRO trials.
    Am J Hematol. 2020 Oct 7. doi: 10.1002/ajh.26015.

    September 2020
  247. DEBEER T, Jordan LC, Lee CA, Patel NJ, et al
    Evidence of transfusion-induced reductions in cerebral capillary shunting in sickle cell disease.
    Am J Hematol. 2020;95:E228-E230.

  248. SONI S
    Gene therapies for transfusion dependent beta-thalassemia: Current status and critical criteria for success.
    Am J Hematol. 2020;95:1099-1112.
    PubMed     Abstract available

  249. GALADANCI NA, Abdullahi SU, Ali Abubakar S, Wudil Jibir B, et al
    Moderate fixed-dose hydroxyurea for primary prevention of strokes in Nigerian children with sickle cell disease: Final results of the SPIN trial.
    Am J Hematol. 2020;95:E247-E250.

  250. GEORGE A, Dinu B, Estrada N, Minard CG, et al
    Novel dose escalation to predict treatment with hydroxyurea (NDEPTH): A randomized controlled trial of a dose-prediction equation to determine maximum tolerated dose of hydroxyurea in pediatric sickle cell disease.
    Am J Hematol. 2020;95:E242-E244.

  251. KNISELY MR, Pugh N, Kroner B, Masese R, et al
    Patient-reported outcomes in sickle cell disease and association with clinical and psychosocial factors: Report from the sickle cell disease implementation consortium.
    Am J Hematol. 2020;95:1066-1074.
    PubMed     Abstract available

  252. TISDALE JF, Pierciey FJ Jr, Bonner M, Thompson AA, et al
    Safety and feasibility of hematopoietic progenitor stem cell collection by mobilization with plerixafor followed by apheresis vs bone marrow harvest in patients with sickle cell disease in the multi-center HGB-206 trial.
    Am J Hematol. 2020;95:E239-E242.

  253. SCARAMELLINI N, Consonni D, Cassinerio E, Arighi C, et al
    A holistic approach to iron chelation therapy in transfusion-dependent thalassemia patients with serum ferritin below 500 mug/L.
    Am J Hematol. 2020;95:E230-E232.

  254. SIDANA S, Murray DL, Dasari S, Go RS, et al
    Glycosylation of immunoglobulin light chains is highly prevalent in cold agglutinin disease.
    Am J Hematol. 2020;95:E222-E225.

  255. TSEU B, Siow W, Pushkaran B, Cheesebrough B, et al
    Beta thalassemia major and Noonan syndrome - Two genetic disorders manifest in the blood film.
    Am J Hematol. 2020;95:1113-1114.

    April 2020
  256. AL-BUBSEREE B, Leach M, Jones R, Bain BJ, et al
    The hematological effects of copper deficiency.
    Am J Hematol. 2020;95:446.

  257. ESPINOZA J, Shah P, Veluswamy S, Zeltzer L, et al
    Aura and mental stress are associated with reports of pain in sickle cell disease-a pilot study using a mobile application.
    Am J Hematol. 2020;95:E101-E103.

  258. DUTTA D, Li K, Methe B, Lim SH, et al
    Rifaximin on intestinally-related pathologic changes in sickle cell disease.
    Am J Hematol. 2020;95:E83-E86.

  259. VACLAVU L, Petr J, Petersen ET, Mutsaerts HJMM, et al
    Cerebral oxygen metabolism in adults with sickle cell disease.
    Am J Hematol. 2020;95:401-412.
    PubMed     Abstract available

  260. GONDELAUD F, Connes P, Nader E, Renoux C, et al
    Sialic acids rather than glycosaminoglycans affect normal and sickle red blood cell rheology by binding to four major sites on fibrinogen.
    Am J Hematol. 2020;95:E77-E80.

    January 2020
  261. WALSH K, Blalock DV, Mehler PS
    Hematologic Findings in a Large Sample of Patients with Anorexia Nervosa and Bulimia Nervosa.
    Am J Hematol. 2020 Jan 15. doi: 10.1002/ajh.25732.

  262. QASRAWI A, Arora R, Ramlal R, Munker R, et al
    Allogenic hematopoietic stem cell transplantation for prolonged bone marrow aplasia after chimeric antigen receptor (CAR) T-cell therapy for relapsed diffuse large B-cell lymphoma.
    Am J Hematol. 2020 Jan 9. doi: 10.1002/ajh.25725.

Thank you for your interest in scientific medicine.

AMEDEO Anemia is free of charge.